Meta-analysis by Yu et al. (2019) revealed an increased risk of colorectal, ovarian, cervical and kidney cancers associated with methylation of the SFRP4 promoter, while no such risk was found for endometrial and stomach cancers. Here, SFRP4 is linked to gastric cancer.